Quantcast
Last updated on April 24, 2014 at 1:21 EDT

Latest Doxorubicin Stories

2012-02-23 07:00:00

SOUDERTON, Pa., Feb. 23, 2012 /PRNewswire/ -- Galen, a Northern Ireland Pharmaceutical company, has acquired the chemotherapy agent, DaunoXome(®) (daunorubicin citrate liposome injection) from Gilead Sciences, Inc. Galen US, Inc., a wholly owned subsidiary of Galen Ltd., will market DaunoXome(®) in the United States. To view the multimedia assets associated with this release, please click:...

FDA Rushes To Fix Shortage Of Cancer Drugs
2012-02-21 15:03:31

The Food and Drug Administration (FDA) announced plans on Tuesday to help resupply the U.S. with two leading cancer drugs. The agency said they will address shortages of two leading cancer drugs by allowing one of them to be imported from abroard, and rush approval for a new manufacturer to make the second. "We're not out of the woods," Dr Sandra L Kweder of the Food and Drug Administration's drug center told the New York Times. "But these two particular shortages have been very, very...

2012-02-14 11:55:00

WHITE PLAINS, N.Y., Feb. 14, 2012 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) has been acutely aware of the dire shortage of drugs used to treat patients with cancer since the matter first emerged last fall. There have been a number of drugs on the shortage list that specifically impact patients with a blood cancer, and this week in particular, attention has turned to the limited supplies of Methotrexate, a drug used to treat children with acute lymphocytic leukemia as well...

2012-01-30 00:30:00

SEATTLE, Jan. 30, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that it has voluntarily withdrawn its New Drug Application ("NDA") for Pixuvri (pixantrone) for the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma ("NHL") in patients who failed two or more lines of prior therapy. The NDA was withdrawn because, after communications with the U.S. Food and Drug Administration ("FDA"), CTI needed additional time to prepare for the...

2012-01-26 06:30:00

QUÉBEC CITY, Jan. 26, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that Jacek Pinski, MD, PhD, Associate Professor of Medicine at the Norris Comprehensive Cancer Center of the University of Southern California, will present updated interim results from a Phase 1 clinical trial in prostate cancer with AEZS-108 (zoptarelin doxorubicin), the Company's targeted cytotoxic luteinizing hormone releasing hormone ("LHRH")...

2012-01-20 00:30:00

SEATTLE, Jan. 20, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today that, following discussions with the European Medicines Agency's ("EMA") Committee for Medicinal Products for Human Use ("CHMP"), the CHMP may issue an opinion on CTI's Marketing Authorization Application ("MAA") for Pixuvri in mid-February. In the interim, CTI will continue to work with the CHMP on the Summary of Product Characteristics and other labeling items for...

2012-01-10 09:17:00

BETHLEHEM, Pa., Jan. 10, 2012 /PRNewswire/ -- Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today that it has been issued six patents within the last 12 months, bringing the company's total to 15 issued U.S. patents, all of which contain broad claims in the immunoassay space. The issued patents are as follows: Busulfan Immunoassay: U.S....

2012-01-05 06:30:00

Collaboration is part of Aeterna Zentaris' personalized medicine approach for AEZS-108 as a treatment for multiple cancers QUÉBEC CITY, Jan. 5, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that it entered into a collaboration agreement with Ventana Medical Systems, Inc., a member of the Roche Group, to develop a companion diagnostic for the immunohistochemical determination of luteinizing hormone-releasing...

2012-01-03 00:00:00

SEATTLE, Jan. 3, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that on February 9, 2012 the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) will review CTI's resubmitted New Drug Application (NDA) for pixantrone for the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL) in patients who failed two or more lines of prior therapy. ODAC is a panel of experts that evaluates data...

2011-12-20 22:34:55

Women who are at risk for breast cancer may also be at greater risk for heart disease Women who are at risk for breast cancer may also be at greater risk for heart disease, new research has found. The majority of women with hereditary breast and ovarian cancer have a mutated form of the BRCA1 or BRCA2 genes, which normally suppress the growth of breast and ovarian tumors. Dr. Subodh Verma, a cardiac surgeon at St. Michael's Hospital, said his research team was surprised to discover...